Key Highlights
- FDA greenlit Merck’s Lipfendra (enlicitide), marking the first once-daily oral PCSK9 inhibitor available for elevated LDL cholesterol
- Clinical trials demonstrated Lipfendra reduced LDL cholesterol by 60% without any significant adverse reactions
- At $315 monthly, Merck’s pricing strategy undercuts competitor injectable treatments exceeding $500 per month
- Market forecasters anticipate Lipfendra revenues surpassing $350 million by 2027, with long-term potential hitting $5 billion yearly
- Guggenheim maintained its Buy recommendation with a $145 target price for MRK after encouraging Keytruda combination trial results
Shares of Merck climbed approximately 1% during Thursday’s premarket session, reaching $125, following the FDA’s ahead-of-schedule authorization of Lipfendra — a pioneering oral PCSK9 inhibitor — through the regulatory body’s accelerated assessment pathway. Year-to-date in 2026, the pharmaceutical giant’s stock has advanced roughly 18%.
This regulatory clearance represents a significant achievement for Merck. Lipfendra, marketed under the generic name enlicitide, becomes the first tablet formulation capable of blocking PCSK9, a protein responsible for regulating LDL cholesterol — frequently referred to as “harmful cholesterol.” Previously, PCSK9-blocking therapies existed exclusively as injectable medications.
Heart-related conditions remain the primary mortality cause worldwide and represent approximately one-quarter of all fatalities in the United States. Statin medications have served as the standard therapy since the 1980s, yet they prove inadequate for numerous patients, especially those suffering from genetically inherited elevated cholesterol.
Clinical testing across two separate trials revealed that Lipfendra decreased LDL cholesterol concentrations by 60%. The medication demonstrated no severe adverse events, although roughly 7% of trial participants experienced gastrointestinal discomfort. An extended study monitoring cardiovascular events including heart attacks and strokes continues, with completion anticipated in 2029.
Competitive Landscape With Strategic Pricing
Merck is launching into a therapeutic space currently dominated by injectable PCSK9 medications. Amgen’s Repatha achieved $900 million in first-quarter 2026 revenue, representing a 34% year-over-year increase. Novartis’s Leqvio recorded $400 million during the identical timeframe, marking a 76% surge. Regeneron’s Praluent contributed $260 million in 2025 domestic sales.
With a monthly list cost of $315, Lipfendra presents a compelling value proposition compared to injectable alternatives exceeding $500. The pharmaceutical company announced commercial availability within coming weeks.
Industry experts forecast Lipfendra could generate over $350 million in revenue during the following year, with extended projections suggesting $5 billion in annual sales if market adoption meets anticipated levels.
The medication also holds considerable strategic importance. Merck’s oncology blockbuster Keytruda — responsible for $32 billion in yearly revenue — faces patent expiration in 2028. Lipfendra represents a critical component of Merck’s portfolio designed to compensate for that anticipated revenue decline.
Keytruda Development Program Shows Promise
In related news, Guggenheim confirmed its Buy stance and $145 valuation target for MRK on Thursday, referencing encouraging Phase 3 results from collaborative partner Kelun-Biotech. The clinical study evaluated Kelun’s TROP2-targeted antibody-drug conjugate sacituzumab tirumotecan combined with Keytruda in treatment-naive NSCLC patients presenting PD-L1 negative non-squamous disease.
The therapeutic combination demonstrated substantial enhancement in progression-free survival metrics and favorable overall survival patterns compared to standard treatment. Comprehensive findings are scheduled for presentation at the ESMO conference this October.
BMO Capital maintains a $142 valuation target for MRK. Scotiabank projects a higher $155 price point, referencing an enhanced valuation multiple in their discounted cash flow modeling. MRK currently trades close to its 52-week peak of $130.29.
AstraZeneca is simultaneously advancing a rival oral PCSK9 inhibitor designated laroprovstat, suggesting Lipfendra’s pioneering market position may face competition relatively soon.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
